Substance / Medication

Triamcinolone

Overview

Active Ingredient
triamcinolone
RxNorm CUI
10759

Indications

Treatment with naltrexone implants should be part of a comprehensive management program that includes psychological and psychosocial support. Naltrexone tablets were initially approved by the FDA in 1985 for the treatment of abuse and addiction of opioids. Naltrexone in oral and extended release injection forms have been approved by the FDA for the treatment and abuse of alcohol. Naltrexone implants may be useful for the treatment of alcohol or opioid dependence in patients who are able to absta

Labeler: Complete Pharmacy and Medical SolutionsUpdated: 2018-03-19T00:00:00.000ZFull label on DailyMed

Contraindications

When this intervention should not be used

Naltrexone is contraindicated in: PRECAUTIONS Patients receiving opioid analgesics (see). WARNINGS Patients with current physiologic opioid dependence (see). WARNINGS Patients in acute opiate withdrawal (see). Any individual who has failed the naloxone challenge test or has a positive urine screen f

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Detailed dosage and administration information is available in the full FDA drug label.

View full prescribing information on DailyMed

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

Clinical Trials

104 trials linked to this intervention

104
Total Trials
34
Recruiting
23
With Results

Research Evidence

Published studies and systematic reviews

Sort:
Triamcinolone application following internal urethrotomy for reducing urethral stricture recurrence rate: a systematic review and meta-analysis of randomized controlled trials.
Andhika Dimas Panca, Djojodimedjo Tarmono, Hidayatullah Furqan et al. · Arch Ital Urol Androl · 2025
PMID: 41031775Meta-Analysis
Triamcinolone injection in the treatment of lid retraction for thyroid-associated ophthalmopathy: A systematic review.
Badjrai Rona Ali, Eldinia Lourisa Ruth, Anandi Lazuardiah et al. · Eur J Ophthalmol · 2025
PMID: 38751133Meta-Analysis
Efficacy and clinical outcomes of suprachoroidal triamcinolone acetonide in diabetic macular edema patients: a single-arm systematic review and meta-analysis.
Karam Mohammad, Baeshen Moath, Abbas Khaldon et al. · Graefes Arch Clin Exp Ophthalmol · 2025
PMID: 40762816Meta-Analysis
Ultrasound-Guided Triamcinolone Injections for Hidradenitis Suppurativa Lesions: A Systematic Review and Meta-Analysis.
Hickerson Natalie, Lam Thao Kimmy, Lev-Tov Hadar · J Ultrasound Med · 2025
PMID: 40530791Meta-AnalysisFull text (PMC)
Intravitreal Triamcinolone Acetonide for Diabetic Macular Edema and Macular Edema Secondary to Retinal Vein Occlusion: A Meta-Analysis.
Mihalache Andrew, Hatamnejad Amin, Patil Nikhil S et al. · Ophthalmologica · 2024
PMID: 37579730Meta-AnalysisFull text (PMC)

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Adverse reaction and safety data for this drug is sourced from the FDA-approved label.

View adverse reactions & drug interactions on DailyMed

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Health Goals

Goals connected through associated conditions

Quick Facts

Type
Substance / Medication
Fully Specified Name
Triamcinolone (substance)
SNOMED CT
116594009
UMLS CUI
C0040864
RxNorm CUI
10759
Labeler
Complete Pharmacy and Medical Solutions

Clinical Data

This intervention maps to 34 entities in the Ltrl knowledge graph.

20
Conditions
7
Biomarkers
5
Specialists
0
Symptoms
104
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.